[1] Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target[J]. Annu Rev Med, 2002, 53:35-57.
[2] Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2 [J]. Annu Rev Pharmacol Toxicol, 1998, 38: 97-120.
[3] Wang R, Wang X, Lin F, et al. shRNA-targeted cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells[J]. Mol Cell Biochem, 2008, 317(1-2):179-188.
[4] Evans JF, Kargman SL. Cancer and cyclooxygenase-2 (COX-2) inhibition[J]. Curr Pharm Des, 2004, 10(6):627-634.
[5] Singh B, Berry JA, Sholer A, et al. COX-2 overexpression increases motility and invasion of breast cancer cells[J]. Int J Oncol, 2005, 26(5):1393-1399.
[6] Yan YX, Li WX, Huang YQ, et al.The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function[J]. Prostaglandins Other Lipid Mediat, 2012, 97(1-2): 29-35.
[7] Ye CG, Wu WK, Yeung JH, et al.Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression[J]. Cancer Lett, 2011, 304(2): 90-96.
[8] Chang CH, Shau WY, Kuo CW, et al. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study[J]. Stroke, 2010, 41(9):1884-1890.
[9] Wang HY, Wu MW, Yang AK, et al. COX-2 Gene increases tongue cancer cell proliferation and invasion through VEGF-C pathway[J]. Med Oncol, 2011, 28(Suppl 1):S360-S366.
[10] Surh YJ, Kundu JK. Signal transduction network leading to COX-2 induction: a road map in search of cancer chemopreventives[J].Arch Pharm Res, 2005, 28(1): 10-15.
[11] Rudner J, Elsaesser SJ, Müller AC, et al. Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2,and Bcl-xl on Celecoxib-induced apoptosis[J]. Biochem Pharmacol, 2010, 79(1): 10-20. |